Asset Details
Do you wish to reserve the book?
Use of proteomic patterns in serum to identify ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Use of proteomic patterns in serum to identify ovarian cancer
Do you wish to request the book?
Use of proteomic patterns in serum to identify ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Use of proteomic patterns in serum to identify ovarian cancer
2002
Overview
New technologies for the detection of early-stage ovarian cancer are urgently needed. Pathological changes within an organ might be reflected in proteomic patterns in serum. We developed a bioinformatics tool and used it to identify proteomic patterns in serum that distinguish neoplastic from non-neoplastic disease within the ovary.
Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionisation). A preliminary “training” set of spectra derived from analysis of serum from 50 unaffected women and 50 patients with ovarian cancer were analysed by an iterative searching algorithm that identified a proteomic pattern that completely discriminated cancer from non-cancer. The discovered pattern was then used to classify an independent set of 116 masked serum samples: 50 from women with ovarian cancer, and 66 from unaffected women or those with non-malignant disorders.
The algorithm identified a cluster pattern that, in the training set, completely segregated cancer from non-cancer. The discriminatory pattern correctly identified all 50 ovarian cancer cases in the masked set, including all 18 stage I cases. Of the 66 cases of non-malignant disease, 63 were recognised as not cancer. This result yielded a sensitivity of 100% (95% CI 93–100), specificity of 95% (87–99), and positive predictive value of 94% (84–99).
These findings justify a prospective population-based assessment of proteomic pattern technology as a screening tool for all stages of ovarian cancer in high-risk and general populations.
Publisher
Elsevier Ltd,Lancet,Elsevier Limited
Subject
/ Biological and medical sciences
/ Cancer
/ Cysts
/ Female
/ Genital system. Mammary gland
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Investigative techniques, diagnostic techniques (general aspects)
/ Lasers
/ Ovarian Neoplasms - diagnosis
/ Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
/ Peptides
/ Proteins
/ Proteome - isolation & purification
/ Software
/ Training
/ Tumors
